96. Crohn disease Clinical trials / Disease details


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01765998
(ClinicalTrials.gov)
February 20136/1/2013The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of InflammationCrohn's DiseaseDrug: Probiotic;Drug: PlaceboThe Baruch Padeh Medical Center, PoriyaNULLNot yet recruiting18 Years60 YearsBoth60Phase 4Israel
2NCT01078935
(ClinicalTrials.gov)
December 20121/3/2010The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of InflammationThe Effect of Probiotics on Bowel DiseaseCrohn's Disease;Ulcerative ColitisDietary Supplement: probiotics;Dietary Supplement: placeboThe Baruch Padeh Medical Center, PoriyaMinistry of Health, IsraelNot yet recruiting18 Years80 YearsBoth100Phase 4NULL
3NCT00587041
(ClinicalTrials.gov)
February 200621/12/2007Use of Oral Probiotics to Reduce Urinary Oxalate ExcretionUse of Oral Probiotics to Reduce Urinary Oxalate ExcretionNephrolithiasis;Hyperoxaluria;Crohn's DiseaseDietary Supplement: Oxadrop;Dietary Supplement: Agri-King Synbiotic (AKSB);Other: PlaceboMayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH);National Center for Complementary and Integrative Health (NCCIH);National Center for Research Resources (NCRR)Completed18 YearsN/AAll40Phase 1/Phase 2United States
4NCT00510978
(ClinicalTrials.gov)
January 20022/8/2007Probiotics in GastroIntestinal DisordersOne Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative ColitisUlcerative Colitis;Crohn's DiseaseBiological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: PlaceboUniversity College CorkEuropean CommissionActive, not recruitingN/A75 YearsBoth360Phase 2/Phase 3Ireland